CRSP CRISPR Therapeutics AG - Common Shares
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 3, 2026
$55,43
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$44,12minimo 52 sett.
$78,48massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
Ricavi (TTM)
$13M
i tuoi badge
Intervallo 52 sett.
$44–$78
Rating Analisti
BUY
Prezzo Obiettivo
$88
P/E
-11.8
ROE
-26.1%
Margine di Profitto Netto
-3368.7%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
CRSP Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$55.43
Capitalizzazione di Mercato (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
Ricavi (TTM)
$13M
ROE (TTM)
-26.1%
Intervallo 52 sett.
$44–$78
CRSP Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Informazioni su CRISPR Therapeutics AG - Common Shares Panoramica della società da Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaBiotechnology
paeseCH
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$4M2016-12-31 → 2025-12-31
EPS$-6.472017-12-31 → 2025-12-31
Flusso di cassa libero$-346M2016-12-31 → 2025-12-31
Margine netto-3368.7%2016-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | CRSP | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -11.8media 5 anni ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 400.1media 5 anni ≈841.4 | ≈841.4 | · | · | |
| P/B (MRQ) | 3.1media 5 anni ≈2.2 | ≈2.2 | · | · | |
| Prezzo / FCF (TTM) | -14.4media 5 anni ≈-9.9 | ≈-9.9 | · | · | |
| Prezzo / Flusso di cassa (TTM) | -14.5media 5 anni ≈-10.6 | ≈-10.6 | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 2.8media 5 anni ≈2.2 | ≈2.2 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | CRSP | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | -3990.0%media 5 anni ≈-15278.7% | ≈-15278.7% | · | · | |
| Margine EBITDA (TTM) | -3850.4%media 5 anni ≈-14752.4% | ≈-14752.4% | · | · | |
| Margine ante imposte (TTM) | -3346.1%media 5 anni ≈-14347.2% | ≈-14347.2% | · | · | |
| Margine di Profitto Netto (TTM) | -3368.7%media 5 anni ≈-14364.6% | ≈-14364.6% | · | · | |
| ROA (TTM) | -19.3%media 5 anni ≈-11.7% | ≈-11.7% | -40.4% | Di prim'ordine | |
| ROE (TTM) | -26.1%media 5 anni ≈-15.6% | ≈-15.6% | -46.3% | Di prim'ordine | |
| ROIC | -34.8%media 5 anni ≈-18.3% | ≈-18.3% | -57.7% | Di prim'ordine |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | CRSP | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Rapporto corrente (MRQ) | 17.8media 5 anni ≈17.7 | ≈17.7 | 7.8 | Liquidità elevata | |
| Quick Ratio | 13.2media 5 anni ≈17.5 | ≈17.5 | 6.5 | Liquidità elevata |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | CRSP | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | -90.6%media 5 anni ≈31552.0% | ≈31552.0% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 43.1%media 5 anni ≈226.6% | ≈226.6% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 37.3% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | CRSP | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.0media 5 anni ≈0.1 | ≈0.1 | · | · | |
| Receivables Turnover (Rotazione dei crediti) | 0.3media 5 anni ≈817.5 | ≈817.5 | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.09%
Prossimo report
Nov 09, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 10, 2026 | $-0.94 | $-1.22 | 23.0% |
| 31 Marzo 2026 | $-1.28 | $-1.25 | -2.5% | |
| 31 Dicembre 2025 | $-1.37 | $-1.18 | -16.4% | |
| 30 Settembre 2025 | $-1.17 | $-1.29 | 9.0% | |
| 30 Giugno 2025 | $-1.29 | $-1.45 | 11.2% | |
| 31 Marzo 2025 | $-1.58 | $-1.28 | -23.9% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.04 | $22.53 | $23.52 | $23.89 | $31.17 | $22.52 | $15.46 | $7.56 | $4.63 | $5.86 | · | |
| Revenue / Share | $0.04 | $0.44 | $4.69 | $0.02 | $11.38 | $0.01 | $5.09 | · | · | · | · | |
| Cash Flow / Share | $-3.84 | $-1.69 | $-3.29 | $-6.38 | $6.70 | $-3.61 | $1.00 | · | · | · | · | |
| Cash / Share | $3.62 | $3.48 | $4.87 | $2.70 | $11.99 | $15.81 | $15.53 | $8.81 | $5.91 | $7.94 | · | |
| EPS (TTM) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-7.05 | · |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.07 | $18.83 | · | $20.41 | $19.36 | $21.18 | · | $22.73 | $23.29 | $24.56 | · | $21.75 | $22.88 | $23.52 | · | $24.97 | |
| Revenue / Share | $0.11 | $0.02 | · | $0.01 | $0.01 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.00 | $0.89 | $1.27 | · | $0.00 | |
| Cash Flow / Share | · | $-1.13 | · | · | · | $-0.63 | · | · | · | $1.34 | · | · | · | $0.11 | · | · | |
| Cash / Share | $3.01 | $4.39 | · | $3.05 | $2.19 | $2.72 | · | $2.64 | $5.70 | $8.34 | · | $6.64 | $5.60 | $4.37 | · | $6.32 | |
| EPS (TTM) | $-4.71 | $-6.17 | · | $-5.56 | $-5.40 | $-4.49 | · | $-2.81 | $-3.21 | $-2.70 | · | $-4.46 | $-5.29 | $-6.71 | · | $-8.52 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $38M | $38M | $38M | · | $203M | $202M | $272M | · | $170M | $170M | $100M | · | $14M | |
| Net Income TTM | $-451M | $-569M | · | $-488M | $-468M | $-386M | · | $-240M | $-266M | $-217M | · | $-354M | $-416M | $-524M | · | $-681M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -11.6 | -7.7 | · | -11.7 | -9.0 | -7.6 | · | -16.7 | -16.8 | -25.2 | · | -10.2 | -10.6 | -6.7 | · | -7.7 | |
| P/S | 393.7 | 1117.5 | · | 158.7 | 113.0 | 78.0 | · | 19.8 | 22.7 | 21.3 | · | 21.2 | 26.2 | 35.6 | · | 362.9 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| Earnings Yield | -8.6% | -13.0% | · | -8.6% | -11.1% | -13.2% | · | -6.0% | -5.9% | -4.0% | · | -9.8% | -9.4% | -14.8% | · | -13.0% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $4M | $37M | $371M | $1M | $915M |
| Margine Operativo % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Utile netto | $-582M | $-366M | $-154M | $-650M | $378M |
| EPS Diluito | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rapporto corrente | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-346M | $-145M | $-270M | $-533M | $457M |
Proprietari istituzionali (13F) 574 filer · $4.3B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
574
Valore detenuto
$4.3B
Nuove posizioni
82
Posizioni chiuse
47
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 82 (-14 vs trimestre precedente) | 47 (-13 vs trimestre precedente) | 158 (-19 vs trimestre precedente) | 157 (+29 vs trimestre precedente) | -2.0M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| ARK Investment Management LLC | $515.999.631 | 9.460.939 | 12,01% | Azioni |
| BlackRock, Inc. | $455.353.197 | 8.348.977 | 10,60% | Azioni |
| Orbis Allan Gray Ltd | $297.197.241 | 5.449.161 | 6,92% | Azioni |
| Capital World Investors | $259.039.094 | 4.749.525 | 6,03% | Azioni |
| STATE STREET CORP | $235.703.664 | 4.321.666 | 5,49% | Azioni |
| GSK plc | $175.652.997 | 3.220.627 | 4,09% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $136.919.043 | 2.509.915 | 3,19% | Azioni |
| VANGUARD GROUP INC | $118.954.581 | 2.268.394 | 2,77% | Azioni |
| SR One Capital Management, LP | $111.194.134 | 2.038.763 | 2,59% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $108.459.389 | 1.988.621 | 2,53% | Azioni |
| FMR LLC | $104.089.735 | 1.908.503 | 2,42% | Azioni |
| Sumitomo Mitsui Trust Group, Inc. | $93.848.832 | 1.720.734 | 2,19% | Azioni |
| Amova Asset Management Americas, Inc. | $93.762.487 | 1.720.097 | 2,18% | Azioni |
| EcoR1 Capital, LLC | $75.771.113 | 1.389.276 | 1,76% | Azioni |
| UBS Group AG | $71.856.395 | 1.317.499 | 1,67% | Azioni |
| Capital International Investors | $69.178.918 | 1.268.407 | 1,61% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $64.457.935 | 1.181.847 | 1,50% | Azioni |
| BANK OF AMERICA CORP /DE/ | $62.999.405 | 1.155.105 | 1,47% | Azioni |
| NEA Management Company, LLC | $57.734.408 | 1.058.570 | 1,34% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57.694.430 | 1.057.837 | 1,34% | Azioni |
| D. E. Shaw & Co., Inc. | $48.748.506 | 893.812 | 1,13% | Azioni |
| MORGAN STANLEY | $47.992.455 | 879.949 | 1,12% | Azioni |
| NORTHERN TRUST CORP | $47.072.983 | 863.091 | 1,10% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35.380.807 | 648.713 | 0,82% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $31.089.982 | 570.040 | 0,72% | Azioni |
| CITADEL ADVISORS LLC | $25.404.514 | 465.796 | 0,59% | Azioni |
| JPMORGAN CHASE & CO | $24.569.275 | 431.669 | 0,57% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.298.288 | 427.178 | 0,54% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $20.836.025 | 382.032 | 0,49% | Azioni |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20.833.789 | 381.991 | 0,49% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.456.336 | 338.400 | 0,43% | Opzione Put |
| Bank of New York Mellon Corp | $17.821.531 | 326.761 | 0,41% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17.763.678 | 325.700 | 0,41% | Opzione Call |
| Logos Global Management LP | $16.362.000 | 300.000 | 0,38% | Azioni |
| CITADEL ADVISORS LLC | $15.822.054 | 290.100 | 0,37% | Opzione Put |
| Squarepoint Ops LLC | $15.641.472 | 286.789 | 0,36% | Azioni |
| Jump Financial, LLC | $15.159.502 | 277.952 | 0,35% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $15.034.803 | 275.375 | 0,35% | Azioni |
| GOLDMAN SACHS GROUP INC | $14.855.182 | 272.372 | 0,35% | Azioni |
| NORGES BANK | $14.767.032 | 270.756 | 0,34% | Azioni |
| WELLS FARGO & COMPANY/MN | $14.353.246 | 263.169 | 0,33% | Azioni |
| CITADEL ADVISORS LLC | $13.973.148 | 256.200 | 0,33% | Opzione Call |
| AMERIPRISE FINANCIAL INC | $13.669.977 | 250.614 | 0,32% | Azioni |
| Vestmark Advisory Solutions, Inc. | $13.213.188 | 242.266 | 0,31% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $12.652.626 | 231.988 | 0,29% | Azioni |
| JANE STREET GROUP, LLC | $12.566.016 | 230.400 | 0,29% | Opzione Call |
| PEAK6 LLC | $11.633.382 | 213.300 | 0,27% | Opzione Put |
| Nuveen, LLC | $11.076.474 | 203.089 | 0,26% | Azioni |
| ROYAL BANK OF CANADA | $9.438.000 | 173.045 | 0,22% | Azioni |
| Marex Group Ltd | $9.303.652 | 170.584 | 0,22% | Azioni |
Attivisti e proprietari del 5%+ 6 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 depositi | 16 Febbraio 2021 | · | Deposito iniziale | · | SEC |
| GlaxoSmithKline plc ×5 depositi | 10 Luglio 2020 | · | Deposito iniziale | · | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 depositi | 04 Febbraio 2020 | · | Deposito iniziale | · | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 depositi | 07 Giugno 2019 | · | Deposito iniziale | · | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 depositi | 08 Febbraio 2018 | · | Deposito iniziale | · | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 depositi | 16 Gennaio 2018 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 32 insider · 12 dirigenti · 16 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 Marzo 2026 M | 255.501 | 0 | 9 | $-10.756.932 |
| Brendan Smith | Chief Financial Officer | 18 Febbraio 2023 M | 5.072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 Marzo 2021 M | 1.891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 Marzo 2025 M | 10.544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 Agosto 2022 A | 26.797 | 0 | 0 | $0 |
| James R. Kasinger | General Counsel and Secretary | 22 Settembre 2026 M | 94.784 | 0 | 6 | $-1.272.398 |
| Naimish Patel | Chief Medical Officer | 29 Maggio 2026 A | 19.357 | 1 | 2 | $-312.892 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 Ottobre 2023 A | 4.411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 03 Dicembre 2021 M | 52.364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 Gennaio 2018 M | 25.204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 Giugno 2017 A | · | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 Ottobre 2016 C | 505.617 | 0 | 0 | $0 |
| Ali Behbahani | Direttore | 17 Settembre 2026 M | 16.637 | 0 | 1 | $-780.934 |
| Christian Rommel | Direttore | 05 Giugno 2026 A | · | 0 | 0 | $0 |
| Harold Edward Fleming | Direttore | 05 Giugno 2026 A | · | 0 | 0 | $0 |
| Douglas A Treco | Direttore | 05 Giugno 2026 A | 22.000 | 0 | 0 | $0 |
| Briggs Morrison | Direttore | 05 Giugno 2026 A | · | 0 | 0 | $0 |
| Katherine A High | Direttore | 05 Giugno 2026 A | · | 0 | 0 | $0 |
| John Greene | Direttore | 05 Giugno 2026 A | 7.000 | 0 | 0 | $0 |
| Simeon George | Direttore | 05 Giugno 2026 A | 1.730.179 | 0 | 0 | $0 |
| Maria Fardis | Direttore | 05 Giugno 2026 A | · | 0 | 0 | $0 |
| Sandesh Mahatme | Direttore | 05 Giugno 2026 A | · | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Direttore | 09 Giugno 2022 A | 148.831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Direttore | 19 Novembre 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Direttore | 18 Dicembre 2018 S | 1.171.268 | 0 | 0 | $0 |
| Thomas Woiwode | Direttore | 15 Giugno 2018 A | 640.014 | 0 | 0 | $0 |
| Anthony N Coles | Direttore | 31 Maggio 2017 A | 70.000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Proprietario del 10% | 04 Dicembre 2017 S | 3.722.534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | Proprietario del 10% | 24 Ottobre 2016 C | 744.380 | 0 | 0 | $0 |
| GSK plc | Proprietario del 10% | 24 Ottobre 2016 C | 3.220.627 | 0 | 0 | $0 |
| Raju Prasad | · | 07 Agosto 2026 G | 14.815 | 0 | 10 | $-5.100.841 |
| Rodger Novak | · | 30 Giugno 2021 S | 573.007 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 27 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,53% | 22.018 NS | 31 Luglio 2026 | N-PORT |
| IDNA · iShares Trust | 1,46% | 71.206 SH | 11 Settembre 2026 | Giornaliero |
| LABU · Direxion Shares ETF Trust | 0,66% | 68.253 NS | 31 Luglio 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 6.830 SH | 01 Ottobre 2026 | Giornaliero |
| IBB · iShares Trust | 0,35% | 685.566 SH | 11 Settembre 2026 | Giornaliero |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70.696 SH | 19 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,16% | 2.381.008 SH | 11 Settembre 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536.446 SH | 19 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,14% | 44.639 NS | 31 Luglio 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,11% | 6.860 SH | 01 Ottobre 2026 | Giornaliero |
| ESML · iShares Trust | 0,06% | 34.534 SH | 11 Settembre 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1.106.455 SH | 19 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | 0,04% | 5.543 SH | 11 Settembre 2026 | Giornaliero |
| IWO · iShares Trust | 0,04% | 115.267 SH | 11 Settembre 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13.170 SH | 19 Agosto 2026 | Giornaliero |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 1.727 SH | 01 Ottobre 2026 | Giornaliero |
| XT · iShares Trust | 0,03% | 21.859 SH | 11 Settembre 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7.774 SH | 19 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20.627 SH | 19 Agosto 2026 | Giornaliero |
| IYY · iShares Trust | 0,01% | 4.231 SH | 11 Settembre 2026 | Giornaliero |
| ITOT · iShares Trust | 0,01% | 128.500 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,01% | 25.737 SH | 11 Settembre 2026 | Giornaliero |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75.392 SH | 19 Agosto 2026 | Giornaliero |
| IWN · iShares Trust | · | 760.375 SH | 11 Settembre 2026 | Giornaliero |
| ISCB · iShares Trust | · | 4.191 SH | 11 Settembre 2026 | Giornaliero |
| ISCV · iShares Trust | · | 20.690 SH | 11 Settembre 2026 | Giornaliero |
| SMLF · iShares Trust | · | 58.519 SH | 11 Settembre 2026 | Giornaliero |
CRSP Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 28 analisti
COMPRA
Target mediano
$80.00
+44,3%
6 21,4%
Acquisto forte
11 39,3%
Compra
11 39,3%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
18 analisti · 2026-10-03Target medio $87.56 +58,0%
Ora
Prezzo attuale $55.43
Basso$44.00
Media$87.56
Alto$291.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
Ultime notizie Notizie recenti che menzionano questa società
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Nasdaq · 3 settimane, 1 giorno fa
Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
Yahoo Finance · 2 mesi, 2 settimane fa
2 Beaten-Down Stocks With Massive Upside Potential
Nasdaq · 2 mesi, 3 settimane fa
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
Yahoo Finance · 3 mesi, 3 settimane fa
Il titolo di CRISPR Therapeutics è assurdamente economico: ecco perché gli analisti prevedono un potenziale di rialzo del 437%.
Nasdaq · 3 mesi, 4 settimane fa
Leadership di Crescita Mega-Cap o Potenziale di Crescita Small-Cap? VUG vs. VBK
Nasdaq · 3 mesi, 4 settimane fa
1 Un Analista di Wall Street di Primo Piano Pensa Che CRISPR Therapeutics Potrebbe Più Che Raddoppiare. Dovresti Comprare Azioni a Manate?
Yahoo Finance · 4 mesi, 2 settimane fa
Rilevante deflusso ETF rilevato - ARKK, CRSP, TEM, HOOD
Nasdaq · 5 mesi, 2 settimane fa
Questa azienda biotech ha una pipeline che potrebbe ridefinire la sua intera area terapeutica
Nasdaq · 5 mesi, 3 settimane fa
Cathie Wood Va Alla Caccia di Occasioni: 2 Azioni che Ha Appena Comprato
Nasdaq · 5 mesi, 3 settimane fa
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 3, 2026